As global markets navigate a mixed landscape marked by the end of the longest U.S. government shutdown and cautious monetary policy signals, Asian tech stocks present intriguing opportunities amidst these shifting dynamics. With small-cap stocks showing sensitivity to interest rate movements, identifying high-growth tech companies in Asia requires a keen focus on innovation potential and resilience to broader economic pressures.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medy-Tox Inc. is a South Korean biopharmaceutical company with a market cap of ₩891.46 billion, focusing on the development and commercialization of botulinum toxin products and other related therapies.
Operations: Medy-Tox generates revenue primarily from its biotechnology segment, amounting to ₩234.63 billion. The company focuses on the development and commercialization of botulinum toxin products and related therapies within this sector.
Medy-Tox, a standout in the biotech sector, showcases impressive financial agility with earnings growth of 296.5% over the past year, significantly outpacing its industry’s average of 39.9%. This surge is underlined by a robust annual earnings forecast set to climb by 49% annually. Despite facing challenges such as a substantial one-off loss of ₩8.2B last year, the company’s revenue growth remains vigorous at 15.7% per year, surpassing Korea’s market average of 11.5%. Medy-Tox continues to innovate and expand its market presence, recently declaring a cash dividend which reflects its positive free cash flow and commitment to shareholder returns.
KOSDAQ:A086900 Earnings and Revenue Growth as at Nov 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Unimicron Technology Corp. specializes in the development, manufacturing, processing, and sale of printed circuit boards and electronic products globally, with a market capitalization of approximately NT$262.16 billion.
Operations: The company generates revenue primarily from the sale of printed circuit boards and electronic products, with significant contributions from Taiwan (NT$88.64 billion) and Mainland China (NT$52.63 billion).
Despite recent challenges, including a one-off loss of NT$1.5B, Unimicron Technology’s resilience is evident with a revenue increase to TWD 96.55 billion this year from TWD 85.99 billion last year, marking a growth rate of 15.7%. This performance notably surpasses the Taiwanese market average growth of 13%. Moreover, the company’s earnings are projected to surge by an impressive 69.3% annually, outpacing the broader market forecast of 20.1% growth per year. With such robust financial metrics and strategic positioning in high-growth tech sectors in Asia, Unimicron is poised for future advancements despite its current profit margin at a modest 2.5%, down from last year’s 7.1%.
TWSE:3037 Revenue and Expenses Breakdown as at Nov 2025
Simply Wall St Growth Rating: ★★★★★★
Overview: Fositek Corp. specializes in the design and manufacturing of metal stamping products across Asia, the United States, and Europe with a market cap of NT$100.43 billion.
Operations: With a primary focus on electronic components and parts, Fositek Corp. generates revenue of NT$11.21 billion from this segment. The company’s operations span Asia, the United States, and Europe.
Fositek’s recent performance underscores its potential within Asia’s high-growth tech sector, with a significant uptick in both sales and earnings. In the latest quarter, sales more than doubled to TWD 3.57 billion from TWD 1.99 billion year-over-year, while net income surged to TWD 687 million from TWD 334 million. This robust growth trajectory is further highlighted by annualized revenue and earnings growth rates of 37.7% and 51.2%, respectively, outstripping broader market averages significantly. Fositek’s aggressive R&D investment strategy, allocating substantial resources towards innovation—evidenced by its current R&D expenditure trend—positions it well for sustained advancements in technology sectors crucial for future industry leadership.
TWSE:6805 Earnings and Revenue Growth as at Nov 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A086900 TWSE:3037 and TWSE:6805.
